Head-to-head evidence
LOXO-338 vs Surzetoclax
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCL-2 · full Multiple Myeloma pipeline
LOXO-338
Developed by Eli Lilly
NCT05024045 · Phase 1 · completed
This trial had no placebo or active comparator group and no blinding; it enrolled a small group of patients across escalating doses to work out a safe dose level and get an early look at tumor responses. That open, single-arm design can flag safety issues and hint at activity, but it cannot show whether LOXO-338 works better than no treatment or another therapy. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
This is an interim analysis reported before the study completed enrollment.
Surzetoclax
Developed by AbbVie
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2030 · NCT06953960 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LOXO-338's landscape · Surzetoclax's landscape